Tag
NASDAQ: TEM
- Tempus AI wins FDA clearance for fourth ECG tool targeting mitral regurgitation
- Tempus AI buys Personalis to strengthen AI‑driven cancer monitoring platform
- Cambridge researchers develop urine test that could detect lung cancer years earlier
- Eli Lilly inks USD$2.75B AI drug deal with Insilico Medicine
- Tempus AI, Daiichi Sankyo team up to boost cancer drug trials with AI
- Mark Zuckerberg backs AI‑biology project to predict, prevent, and treat disease
- The promises and perils of artificial intelligence: a Mugglehead roundup
- Alibaba Group gets FDA nod for cancer detection tool
- Personalis Inc share price jumps 50% on deals with Merck and Moderna